With the possibility for extension, the patent entitled ‘Fusidic Acid Dosing Regimens for Treatment of Bacterial Infections’ protects US market exclusivity to 2029.
Cempra chief executive officer Prabhavathi Fernandes said taksta is an antibiotic candidate, currently in a Phase 2 clinical study in patients with prosthetic joint infections.
"Our now proprietary loading dose regimen for Taksta was a novel innovation designed so that the drug would rapidly reach therapeutic blood levels and minimize the risk of drug resistance," Fernandes added.
"The patent provides protection in addition to the expected U.S. market exclusivity obtained through Waxman-Hatch, the GAIN Act, pediatric testing and, possibly, the Orphan Drug Act."
North Carolina-based Cempra is focused on developing differentiated antibiotics against bacterial infectious diseases.